Boston Heart Diagnostics is a specialized clinical laboratory focused on providing advanced cardiovascular disease (CVD) risk assessment and comprehensive diagnostic testing. Founded in 2007, the company offers unique biomarker analysis and personalized health reports to help clinicians and patients prevent and manage heart disease. Boston Heart Diagnostics became a subsidiary of Eurofins Scientific in 2015, integrating its specialized services into Eurofins' global network of laboratories. They are committed to innovation in CVD diagnostics, offering tests related to cholesterol balance, genetics, and inflammation to guide personalized treatment strategies.
Primary clinical laboratory for advanced cardiovascular disease testing, research, development, and sample processing. This facility houses the scientific and operational teams.
State-of-the-art laboratory equipped for comprehensive lipid profiling, genetic testing, inflammation biomarker analysis, and other specialized cardiovascular diagnostic assays.
The work culture emphasizes scientific rigor, innovation in diagnostics, and a patient-centric approach. As part of Eurofins, there's a focus on quality, accuracy, and collaboration within a larger scientific community.
This facility serves as a key center for Eurofins' specialized cardiovascular diagnostic services in the United States, developing and performing tests that provide critical insights for personalized patient care and CVD prevention.
Boston Heart Diagnostics' services are primarily utilized by healthcare providers within the United States. As a part of Eurofins Scientific, a global leader in bio-analytical testing with an extensive network of laboratories worldwide, Boston Heart Diagnostics benefits from global expertise, research collaborations, and the potential for broader service distribution through the Eurofins international infrastructure. Eurofins supports global functions such as advanced R&D, quality assurance frameworks, and access to a wide range of scientific capabilities.
200 Crossing Boulevard, Suite 100
Framingham
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Boston Heart Diagnostics' leadership includes:
Boston Heart Diagnostics has been backed by several prominent investors over the years, including:
As Boston Heart Diagnostics operates as a specialized unit within Eurofins Scientific, specific executive movements for this division are not typically announced separately from the parent company. Leadership changes, if any, are generally part of broader Eurofins corporate or divisional announcements. No high-profile, publicly disclosed executive hires or exits specifically for the Boston Heart Diagnostics leadership team have been identified in the last 12 months.
Discover the tools Boston Heart Diagnostics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Boston Heart Diagnostics historically had its own email domain, since its acquisition by Eurofins Scientific, communications are often routed through Eurofins' corporate email system. The common format observed for Eurofins employees in the US, including those associated with Boston Heart Diagnostics, is FirstNameLastName@eurofinsus.com.
FirstNameLastName@eurofinsus.com
Format
JaneDoe@eurofinsus.com
Example
85%
Success rate
Genomeweb • March 5, 2024
Eurofins Scientific announced its acquisition of Transplant Genomics Inc. (TGI). Eurofins plans to integrate TGI's portfolio of kidney and heart transplant rejection tests into its US clinical diagnostics business line, which includes Eurofins Viracor, Eurofins CellTx, Eurofins EGL, VRL Eurofins, and Boston Heart Diagnostics. This move aims to enhance Eurofins' offerings in transplant diagnostics....more
PR Newswire • December 12, 2022
Eurofins Viracor, a leader in infectious disease and immunology testing, in partnership with Boston Heart Diagnostics, announced the launch of a novel donor-derived cell-free DNA test, Prospera®, for monitoring immunosuppression in kidney transplant patients. This collaboration highlights the synergy within Eurofins' specialized diagnostic units....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Boston Heart Diagnostics, are just a search away.